Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer

LESSONS LEARNED. Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8, and 11 could be administered safely. Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administe...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Rivero, Jaydira, Edgerly, Maureen, Ward, Jean, Madan, Ravi A., Balasubramaniam, Sanjeeve, Fojo, Tito, Gramza, Ann W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324636/
https://www.ncbi.nlm.nih.gov/pubmed/30297385
http://dx.doi.org/10.1634/theoncologist.2018-0452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324636/
https://www.ncbi.nlm.nih.gov/pubmed/30297385
http://dx.doi.org/10.1634/theoncologist.2018-0452

Ejemplares similares